Cetirizine
Cetirizine, Quzyttir, Zerviate, Zyrtec (cetirizine) is a small molecule pharmaceutical. Cetirizine was first approved as Zyrtec on 1996-09-27. It is used to treat allergic rhinitis perennial and urticaria in the USA. The pharmaceutical is active against histamine H1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cetirizine, Quzyttir, Zerviate, Zyrtec (discontinued: Cetirizine, Zyrtec)
CombinationsCetirizine pseudoephedrine, Zyrtec (discontinued: Cetirizine pseudoephedrine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cetirizine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CETIRIZINE HYDROCHLORIDE ALLERGY | BionPharma | N-022429 OTC | 2009-07-23 | 1 products, RLD |
| CETIRIZINE HYDROCHLORIDE HIVES RELIEF | BionPharma | N-022429 OTC | 2009-07-23 | 2 products, RLD |
| CETIRIZINE HYDROCHLORIDE ALLERGY | BionPharma | N-022429 OTC | 2009-07-23 | 1 products, RLD, RS |
| ZERVIATE | Harrow | N-208694 RX | 2017-05-30 | 1 products, RLD, RS |
| CHILDREN'S ZYRTEC HIVES RELIEF | Johnson & Johnson | N-022155 OTC | 2007-11-16 | 1 products, RLD, RS |
| CHILDREN'S ZYRTEC ALLERGY | Johnson & Johnson | N-022155 OTC | 2007-11-16 | 1 products, RLD, RS |
| CHILDREN'S ZYRTEC ALLERGY | Johnson & Johnson | N-021621 OTC | 2007-11-16 | 2 products, RLD |
| ZYRTEC ALLERGY | Johnson & Johnson | N-022578 OTC | 2010-09-03 | 1 products, RLD, RS |
| ZYRTEC ALLERGY | Johnson & Johnson | N-019835 OTC | 2007-11-16 | 1 products, RLD, RS |
| QUZYTTIR | JDP Therapeutics | N-211415 RX | 2019-10-04 | 1 products, RLD, RS |
Show 5 discontinued
Cetirizine hydrochloride
+
Pseudoephedrine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZYRTEC-D 12 HOUR | Johnson & Johnson | N-021150 OTC | 2007-11-09 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 12 hour allergy d | ANDA | 2020-09-03 |
| 24 hour allergy | New Drug Application | 2024-04-01 |
| all day | ANDA | 2020-06-18 |
| all day allergy | ANDA | 2023-03-20 |
| all day allergy d | ANDA | 2020-08-31 |
| all day allergy relief | ANDA | 2024-08-05 |
| all day allergy relief d | ANDA | 2018-12-06 |
| all day allergy-d | ANDA | 2022-06-13 |
| allergy | ANDA | 2024-06-03 |
| allergy and congestion relief d | ANDA | 2023-05-30 |
Show 128 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cetirizine Hydrochloride, Zerviate, Eyevance | |||
| 9254286 | 2032-07-09 | DP | |
| 8829005 | 2030-03-15 | U-1680 | |
| 9750684 | 2030-03-15 | DP | |
| 9993471 | 2030-03-15 | U-1680 | |
| Cetirizine Hydrochloride, Quzyttir, Jdp | |||
| 8263581 | 2030-02-28 | U-2635 | |
| 8314083 | 2030-02-28 | U-2634 | |
| 8513259 | 2030-02-11 | U-2636 | |
| 9119771 | 2030-02-11 | U-2635 | |
| 9180090 | 2030-02-11 | U-2635 | |
ATC Codes
R: Respiratory system drugs
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AE: Piperazine derivatives, systemic antihistamines
— R06AE07: Cetirizine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GX: Other antiallergics in atc
— S01GX12: Cetirizine
HCPCS
Code | Description |
|---|---|
| J1201 | Injection, cetirizine hydrochloride, 0.5 mg |
Clinical
Clinical Trials
142 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rhinitis | D012220 | EFO_0008521 | J31 | 3 | 9 | 14 | 15 | 7 | 48 |
| Allergic rhinitis | D065631 | — | J30.9 | 2 | 9 | 13 | 15 | 7 | 46 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 7 | 3 | 8 | 4 | 22 |
| Healthy volunteers/patients | — | — | — | 9 | — | 1 | 1 | 2 | 13 |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | 1 | — | 7 | 5 | — | 13 |
| Urticaria | D014581 | EFO_0005531 | L50 | 1 | 1 | 4 | 5 | 1 | 12 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 5 | 1 | — | 3 | 1 | 10 |
| Chronic urticaria | D000080223 | — | L50.8 | — | 1 | 2 | 4 | — | 7 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | 3 | — | 4 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | 1 | 2 | — | 4 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Conjunctivitis | D003231 | HP_0000509 | H10 | — | 2 | 5 | — | — | 6 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 2 | 5 | — | — | 6 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 1 | 1 | 2 | — | 1 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 1 | — | — | 3 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | 1 | — | 1 | 3 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | 1 | — | 1 | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | 1 | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | — | 1 | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | — | — | 1 | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis b | D006509 | — | — | — | 4 | — | — | — | 4 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | 4 | — | — | — | 4 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 4 | — | — | — | 4 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 4 | — | — | — | 4 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | 1 | — | — | 2 | 3 |
| Syndrome | D013577 | — | — | — | 2 | — | — | 1 | 3 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 2 | — | — | — | 2 |
| Nephrosis | D009401 | — | — | — | 2 | — | — | — | 2 |
| Hepatitis d | D003699 | EFO_0007304 | — | — | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 3 | — | — | — | — | 3 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | 1 | — | — | — | — | 1 |
| Prostatitis | D011472 | EFO_0003830 | N41 | 1 | — | — | — | — | 1 |
| Pelvic pain | D017699 | — | — | 1 | — | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
| Larva migrans | D007815 | EFO_0007391 | B76.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 1 | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 1 | 1 |
| Actinic keratosis | D055623 | — | L57.0 | — | — | — | — | 1 | 1 |
| Keratosis | D007642 | — | — | — | — | — | — | 1 | 1 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | — | 1 | 1 |
| Vasomotor rhinitis | D012223 | EFO_0007533 | J30.0 | — | — | — | — | 1 | 1 |
| Peripheral nervous system diseases | D010523 | HP_0009830 | G64 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cetirizine |
| INN | cetirizine |
| Description | Cetirizine is a member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively. It has a role as an anti-allergic agent, a H1-receptor antagonist, an environmental contaminant and a xenobiotic. It is a monocarboxylic acid, a member of piperazines, a member of monochlorobenzenes and an ether. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 83881-51-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1000 |
| ChEBI ID | 3561 |
| PubChem CID | 2678 |
| DrugBank | DB00341 |
| UNII ID | YO7261ME24 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cetirizine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Cetirizine
+
Pseudoephedrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,882 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
52,250 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use